Picture loading failed.

Anti-PVRL4 therapeutic antibody (Pre-made Enfortumab biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Enfortumab vedotin,[1] sold under the brand name Padcev, is an antibody-drug conjugate designed for the treatment of cancer expressing Nectin-4. Enfortumab refers to the monoclonal antibody part, and vedotin refers to the payload drug (MMAE) and the linker.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-182-1mg 1mg Inquiry
GMP-Bios-ab-182-10mg 10mg Inquiry
GMP-Bios-ab-182-100mg 100mg Inquiry
GMP-Bios-ab-182-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-PVRL4 therapeutic antibody (Pre-made Enfortumab biosimilar,Whole mAb ADC)
INN Name Enfortumab
TargetPVRL4
FormatWhole mAb ADC
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusNFD
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2013
Year Recommended2014
CompaniesAgensys;Seattle Genetics
Conditions Approvedna
Conditions ActiveUrogenital cancer
Conditions Discontinuedna
Development Techna